Zachary A. Borman

Zachary A. Borman

Auto-generated profile, based on publicly available information

Zachary A. Borman

A The Henry D. Janowitz Division of Gastroenterology , One Gustave L. Levy Place , New York , NY , USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2018 in Expert Review of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
ZBZachary A. Borman
Zachary A. Borman
JCJustin Côté-Daigneault
Justin Côté-Daigneault
JCJean-Frédéric Colombel
Jean-Frédéric Colombel
Introduction: Crohn’s disease and Ulcerative Colitis are forms of inflammatory bowel disease (IBD), chronic diseases treated with medical and surgical therapy. Patients with IBD are treated with potent immunomodulatory agents, leading to immunosuppression, and the potential for opportunistic infections. In 2014, the ECCO guidelines were released to guide the prevention, diagnosis and treatment of a variety of these opportunistic infections. Since 2014, there have been a number of new agents released as well as a significant expansion in our knowledge of the safety profile of IBD medications. In this paper we review the literature after 2014 regarding opportunistic infections and updates on safety data. Areas covered: We review updates in immunomodulatory therapies for IBD and opportunistic infections since the 2014 ECCO guidelines were published. Expert commentary: The prevention, diagnosis and treatment of opportunistic infections continues to evolve, as new drugs are approved, and the use of a combination of biologic agents are considered for therapy in clinical trials. What causes some patients to fail to respond to vaccination, or for others to develop severe infections, remains unclear. Improved risk stratification for opportunistic infections in IBD patients and updated ECCO 2014 guidelines would be of significant benefit.

19 November 2010 in Blood
Verified
Journal Article
Open access
PMPawel Muranski
Pawel Muranski
ZBZachary Borman
Zachary Borman
SKSid Kerkar
Sid Kerkar
YJYun Ji
Yun Ji
LGLuca Gattinoni
Luca Gattinoni
NRNicholas P Restifo
Nicholas P Restifo
Abstract 1018 Th17 cells are thought to be meta-stable, short-lived end-effector T lymphocytes and purportedly have a limited ability to form memory. Paradoxically, we have recently reported that tumor-specific Th17-polarized CD4+ T cells eradicate established tumor more efficiently than their Th1 counterparts did. Mounting evidence suggests that the advanced differentiation stage of the effectors impairs their self-renewal ability and negatively correlates with the anti-tumor functionality of T cells upon adoptive transfer. We hypothesized that in vivo advantage of Th17-polarized cells over Th1 cells might result from more naïve, less senescent properties preserved during the initial in vitro programming. Using a TCR gene engineered Th17 cells we showed that IL-17A or CCR6 signaling contributed only modestly to tumor rejection, and that Th17-polarized cells had to activate type 1 defining transcription factor tbx21 (t-bet) and secrete IFN-γ in vivo, underscoring the less mature, dualistic nature of type 17 responses. Although we confirmed that Th17-polarized cells acquired an end-effector-like phenotype (CD27low/CD62Llow), we found that they also exhibited lower levels of inhibitory receptors and multiple markers of T cell terminal differentiation. While previous work used IL-17 to trace the fate of Th17 cells, in a congenic system we observed that most type 17 cells lost the capacity to produce IL-17A during in vivo expansion, although they efficiently persisted and formed memory. Serial global gene expression profiling demonstrated the loss of IL-17A expression and the acquisition of a phenotype with Th1-like features, nevertheless the molecular signature of Th17-derived cells remained significantly distinct from that of Th1-derived memory cells. Using gene set enrichment analysis (GSEA) we observed a highly significant non-random distribution of genes associated with less mature memory T cell subset in Th17-derived population. Ex vivo recovered Th17-derived memory cells expressed high levels of genes related to improved survival, functionality and self-renewal, including wnt/β-catenin target tcf-7, thus closely resembling the pattern previously described by us in a self-renewing memory stem-like CD8+ subset generated pharmacologically. We confirmed the activity of this stem-related pathway during the initial Th17 polarization, as evidenced by the striking accumulation of β-catenin and progressive induction of tcf-7 to a level above one found in naïve cells. In summary, we report that Th17-derived cells expressed more “stem-like” characteristics distinct from Th1-derived effectors as evidenced by their molecular signature and dramatically enhanced ability to survive in vivo and reject tumor. This suggests that Th17-polarizing conditions trigger a distinctive developmental program that dissociates proliferation from maturation.

30 March 2023
Verified
Other
Open access
SKSid P. Kerkar
Sid P. Kerkar
PMPawel Muranski
Pawel Muranski
AKAndrew Kaiser
Andrew Kaiser
Andrea BoniAndrea Boni
Andrea Boni
LSLuis Sanchez-Perez
Luis Sanchez-Perez
NRNicholas P. Restifo
Nicholas P. Restifo
Supplementary Figure 4 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

30 March 2023
Verified
Other
Open access
SKSid P. Kerkar
Sid P. Kerkar
PMPawel Muranski
Pawel Muranski
AKAndrew Kaiser
Andrew Kaiser
Andrea BoniAndrea Boni
Andrea Boni
LSLuis Sanchez-Perez
Luis Sanchez-Perez
NRNicholas P. Restifo
Nicholas P. Restifo
Supplementary Figure 7 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

30 March 2023
Verified
Other
Open access
SKSid P. Kerkar
Sid P. Kerkar
PMPawel Muranski
Pawel Muranski
AKAndrew Kaiser
Andrew Kaiser
Andrea BoniAndrea Boni
Andrea Boni
LSLuis Sanchez-Perez
Luis Sanchez-Perez
NRNicholas P. Restifo
Nicholas P. Restifo
T-cell–based immunotherapies can be effective in the treatment of large vascularized tumors, but they rely on adoptive transfer of substantial numbers (∼20 million) of tumor-specific T cells administered together with vaccination and high-dose interleukin (IL)-2. In this study, we report that ∼10,000 T cells gene-engineered to express a single-chain IL-12 molecule can be therapeutically effective against established tumors in the absence of exogenous IL-2 and vaccine. Although IL-12–engineered cells did not perist long-term in hosts, they exhibited enhanced functionality and were detected in higher numbers intratumorally along with increased numbers of endogenous natural killer and CD8+ T cells just before regression. Importantly, transferred T cells isolated from tumors stably overproduced supraphysiologic amounts of IL-12, and the therapeutic effect of IL-12 produced within the tumor microenvironment could not be mimicked with high doses of exogenously provided IL-12. Furthermore, antitumor effects could be recapitulated by engineering wild-type open-repertoire splenocytes to express both the single-chain IL-12 and a recombinant tumor-specific T-cell receptor (TCR), but only when individual cells expressed both the TCR and IL-12, indicating that arrested migration of T cells at the tumor site was required for their activities. Successful tumor eradication was dependent on a lymphodepleting preconditioning regimen that reduced the number of intratumoral CD4+ Foxp3+ T regulatory cells. Our findings reveal an approach to genetically modify T cells to reduce the cell number needed, eliminate the need for vaccines or systemic IL-2, and improve immunotherapy efficacy based on adoptive transfer of gene-engineered T cells. Cancer Res; 70(17); 6725–34. ©2010 AACR.

30 March 2023
Verified
Other
Open access
SKSid P. Kerkar
Sid P. Kerkar
PMPawel Muranski
Pawel Muranski
AKAndrew Kaiser
Andrew Kaiser
ABAndrea Boni
Andrea Boni
LSLuis Sanchez-Perez
Luis Sanchez-Perez
NRNicholas P. Restifo
Nicholas P. Restifo
Supplementary Figure 5 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts